Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 103 results for dexamethasone

  1. Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

    Discontinued Reference number: GID-TA10254

  2. Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

    Discontinued Reference number: GID-TAG511

  3. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]

    In development Reference number: GID-TA11660 Expected publication date: TBC

  4. COVID-19 prescribing briefing: corticosteroids

    Dexamethasone and hydrocortisone are both corticosteroids; they have a role in treating COVID-19 in certain people.

  5. Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467

    Discontinued Reference number: GID-TA10353

  6. Brolucizumab for treating diabetic macular oedema (TA820)

    Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.

  7. Guidance on the use of coronary artery stents (TA71)

    Evidence-based recommendations on using coronary artery stents in adults.

  8. Plitidepsin with dexamethasone for treating multiple myeloma after 3 previous therapies including bortezomib and lenalidomide [ID1081]

    Discontinued Reference number: GID-TA10171

  9. Aflibercept for treating diabetic macular oedema (TA346)

    Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.

  10. Diabetic retinopathy: management and monitoring (NG242)

    This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.

  11. Managed access

    Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.

  12. Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565

    Discontinued Reference number: GID-TA10502

  13. Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy (TA895)

    Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy.